Cite
HARVARD Citation
Roviello, G. et al. (2022). Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study. Cancer medicine. pp. 3084-3092. [Online].